"MANF may also show utility in Glaucoma. Glaucoma

"MANF may also show utility in Glaucoma. Glaucoma affects approximately 4 million people in the U.S. alone. It's a $3 billion market. Data presented at AVRO and TOD provide the basis for moving MANF into human clinical studies in 2015. This creates a very interesting development pathway for Amarantus and a potential development partner - i.e. secure market exclusivity and aggressive pricing with Orphan Drug indications such as RP and RAO, then expand the approval to blockbuster markets like Glaucoma."